EU Revoked Marketing Authorization for Cancer Drug Aumseqa
The European Commission pulled the drug after a ruling found the application used protected data from a rival medication.
Updated on Sept. 30, 2026 in Cancer
Live Poll
Should pharmaceutical companies be permitted to use rival clinical data to gain drug approval?
The European Commission has officially revoked the marketing authorization for the cancer drug Aumseqa. The decision follows a legal challenge regarding the use of protected clinical trial data during the drug's approval process.
Why it matters
This regulatory action highlights the strict enforcement of data protection laws intended to safeguard original pharmaceutical research. Patients and providers should be aware that the drug is currently removed from the market while the applicant pursues a new submission.
The revocation follows a formal determination that the 2022 application for Aumseqa improperly used clinical data from AstraZeneca's Tagrisso, which has been under EU data protection since February 4, 2016. It remains unknown when a corrected application might be resubmitted.
The players
AstraZeneca
A global pharmaceutical company that manufactures Tagrisso, a targeted therapy for lung cancer.
European Commission
The executive branch of the European Union responsible for regulatory authorization of medicinal products.
European Medicines Agency
The EU agency responsible for the scientific evaluation and safety monitoring of medicines.
Hansoh
The pharmaceutical company responsible for developing Aumseqa and managing its regulatory filings.
The details
The dispute centers on regulatory rules that prevent a new drug application from relying on the clinical evidence of an existing, protected product. The original application for Aumseqa utilized data from the Tagrisso FLAURA trial to support its own authorization, violating the eight-year data protection period afforded to the reference drug. Following a legal challenge from AstraZeneca, the European Commission confirmed this breach of requirements.
Timeline
February 4, 2016: Tagrisso began its eight-year EU data protection period.
2022: The application for Aumseqa was submitted by SFL Pharma.
November 2025: The European Medicines Agency recommended the drug for approval.
February 2026: Aumseqa received its initial authorization for use in the EU.
September 25, 2026: The European Commission signed the letter revoking the drug's authorization.
Health Landscape
The revocation underscores the rigid application of the EU drug data protection exclusivity period, which governs the competitive entry of new therapeutic agents. This event follows a pattern of heightened regulatory scrutiny over clinical data usage in the European oncology market.
Patients currently or previously prescribed Aumseqa should speak with their oncologist to determine if their treatment plan needs adjustment. Consult your doctor to discuss alternative therapeutic options that remain authorized for your specific condition.
The takeaway
Regulatory bodies maintain strict protections for clinical trial data to ensure original research integrity. If you have questions about the safety or availability of your current cancer treatment, prioritize a conversation with your healthcare team to review your care plan.
Further reading
For more information on current treatment standards, visit the Cancer section.
Source note: This article includes information reported by FiercePharma.
Live Poll
Should pharmaceutical companies be permitted to use rival clinical data to gain drug approval?
